Evidence map›Paper›PMID 42653475›Full record

ArticleInternational journal of molecular sciences2026

Iron Oxide Nanozyme for Magnetothermal Activation of ER-TRPV1 Enables Efficient Intravesical Therapy of Bladder Cancer.

Galong Li, Dongyan Li, Bin Lan, Yuanyuan Cheng, Hongxia Liang, Wenli Zhang, Xiaopan Xu, Hongbing Lu

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Galong LiSchool of Biomedical Engineering, Fourth Military Medical University, Xi'an 710032, China.ORCID 0000-0003-1095-3625
Dongyan LiSchool of Biomedical Engineering, Fourth Military Medical University, Xi'an 710032, China.
Bin LanSchool of Biomedical Engineering, Fourth Military Medical University, Xi'an 710032, China.
Yuanyuan ChengSchool of Biomedical Engineering, Fourth Military Medical University, Xi'an 710032, China.
Hongxia LiangSchool of Biomedical Engineering, Fourth Military Medical University, Xi'an 710032, China.
Wenli ZhangSchool of Biomedical Engineering, Fourth Military Medical University, Xi'an 710032, China.
Xiaopan XuSchool of Biomedical Engineering, Fourth Military Medical University, Xi'an 710032, China.ORCID 0000-0003-3707-1104
Hongbing LuSchool of Biomedical Engineering, Fourth Military Medical University, Xi'an 710032, China.ORCID 0000-0003-4181-7239

Funding

Key Research and Development Program of Shaanxi Province 2025SF-YBXM-392National Natural Science Foundation of China 82372035National Natural Science Foundation of China 82572373
6 · The paper itself

Abstract

Drug-mediated intravesical therapy is a widely used treatment approach for bladder cancer (BCa), which is limited by poor tumor accumulation and the toxicity of drugs. Herein, a facile approach utilizing magnetic hyperthermia therapy (MHT) for BCa treatment is reported through intravesical instillation of tumor-targeting iron oxide nanoparticles (IONPs), which are coated with anti-FGFR3 antibodies for specific binding to FGFR3 overexpressed on BCa cells. The antibody coating significantly enhanced targeting ability and increased cancer cell uptake. Under an alternating magnetic field (AMF), the IONPs magnetothermally activated TRPV1 on the endoplasmic reticulum (ER) of BCa and induced Ca

Indexed as

Endoplasmic ReticulumHyperthermia, InducedMagnetic Iron Oxide NanoparticlesTRPV Cation ChannelsUrinary Bladder NeoplasmsAdministration, IntravesicalAnimalsApoptosisCell Line, TumorFemaleHumansMiceReceptor, Fibroblast Growth Factor, Type 3FGFR3 protein, humanReceptor, Fibroblast Growth Factor, Type 3TRPV1 protein, humanTRPV Cation Channelsbladder cancerFGFR3intravesical therapymagnetic hyperthermia therapyTRPV1

Identifiers

PMID42653475
PMCPMC13513725

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.